Literature DB >> 1327528

In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factor alpha mediated killing of c-Ha-ras-transformed cells.

B Gonen1, O Kahana, I P Witz.   

Abstract

Cellular subclones of high and low tumorigenicity obtained from a mouse c-Ha-ras-transformed clone, were examined for their sensitivity to tumor-necrosis-factor (TNF)-mediated cytotoxicity. Cells of the highly tumorigenic subclones showed a significantly enhanced resistance to the cytotoxic effect of TNF plus cyclohexamide (CHI) as compared to cells of the low-tumorigenic subclones. The enhanced resistance to TNF+CHI was not due to a lower expression of TNF receptors on the cells. The c-Ha-ras-transfected cells were transformed and maintained in culture only (C cells). In vivo passage of cells of the initially low-tumorigenic c-Ha-ras subclones through the mouse significantly enhanced the tumorigenic potential of these CTC cells (culture/tumor/culture). In correlation with their enhanced tumorigenicity, the CTC cells were highly resistant to TNF-mediated cytotoxicity as compared to C cells of the same subclone. Furthermore, the involvement of TNF in determining the tumorigenic phenotype of the c-Ha-ras-transformed cells was demonstrated in a more direct manner. Cells of a c-Ha-ras-transformed low-tumorigenic, highly TNF-sensitive subclone were selected by repeated cycles of in vitro exposure to TNF alpha. As a result, a stable, highly TNF-resistant population of cells emerged. These TNF-resistant cells caused more tumors in mice as compared to their original TNF-sensitive cells. These results show that the resistance to the cytotoxic effect of TNF plus cyclohexamide may be involved, at least partially, in the tumorigenic potential of c-Ha-ras-transformed cells and suggest a possible role for TNF in the enhancement of the tumorigenic potential of these cells in mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327528     DOI: 10.1007/bf01789017

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

Review 1.  Tumour necrosis factor as an anticancer agent.

Authors:  F R Balkwill; M S Naylor; S Malik
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

Review 2.  Natural killer cells and naturally occurring antibodies as representatives of natural tumor immunity.

Authors:  R Ehrlich; I P Witz
Journal:  Pathobiol Annu       Date:  1982

3.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

4.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

5.  Induction of synthesis of tumor necrosis factor in human and murine cell lines by exogenous recombinant human tumor necrosis factor.

Authors:  Y Niitsu; N Watanabe; H Neda; N Yamauchi; M Maeda; H Sone; H Kuriyama
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

6.  Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.

Authors:  A S Chong; P Scuderi; W J Grimes; E M Hersh
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

7.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

8.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells.

Authors:  M Tsujimoto; Y K Yip; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor.

Authors:  T Himeno; N Watanabe; N Yamauchi; M Maeda; Y Tsuji; T Okamoto; H Neda; Y Niitsu
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.